MDM2 and neoplasm: Activation of p53 with agents such as low-dose actinomycin D,30 MDM2 antagonists,31 or other low-dose DNA damaging agents32 have been shown to induce selective p53 dependent G2 arrest in normal cells without arresting tumour cells, thus permitting selective killing of p53 deficient tumour cells.